Skip to main content

Aviado · Research

Longevity Daily

Saturday, November 14, 2026

Today's Brief

Today's issue is anchored by a Nature Metabolism bombshell: blood NAD levels don't decline with age in healthy adults, directly challenging the core premise behind NMN and NR supplementation. MIT researchers simultaneously revealed why aging brains lose their nightly waste-clearing mechanism, while Stanford built a resting-brain-activity score that predicts Alzheimer's years before memory falters. Our Aviado deep-dive breaks down how Bacopa monnieri's dual action on acetylcholine and GABA sets it apart from most nootropics. And Scott Carney's investigation into David Sinclair is essential reading for anyone watching longevity's hype machine.

10 stories7 peer-reviewed2 trials1 Aviado original

Cognitive Health & Neuroprotection

New ResearchMIT News· 2026-11-13

MIT Discovers Why Aging Brains Lose Their Nightly Waste-Clearing System

MIT researchers found that cerebrospinal fluid waves -- which flush debris from the brain during sleep -- are significantly weaker in older adults, leaving more toxic waste behind overnight. This impaired brain-cleaning process may help explain why amyloid and tau proteins accumulate with age, increasing Alzheimer's risk. The finding puts a spotlight on deep sleep quality as a key lever in brain longevity, not just how many hours you clock.

Read more →
New ResearchScienceAlert· 2026-11-14

Stanford's New Brain Score Predicts Alzheimer's Years Before Memory Fails

Stanford scientists developed a resting-brain-activity score (ARC) using fMRI that predicts who will develop mild cognitive impairment or Alzheimer's -- and it outperforms models combining age, amyloid/tau scans, and APOE genetics. If validated, ARC could identify high-risk individuals for prevention trials years before symptoms emerge. The practical takeaway: brain aging is measurable far earlier than most people realize.

Read more →
Clinical TrialBusiness Insider· 2026-11-14

The Bold New Strategy to Stop Alzheimer's Before It Starts

Several clinical trials are now testing Alzheimer's-modifying drugs in people who show brain changes but have no symptoms yet -- exploiting what researchers describe as a 20-year biological window for intervention. Business Insider examines these unconventional trials and the central trade-off: how much treatment risk would you accept to potentially prevent dementia? This marks a generational shift in Alzheimer's research from treatment to prevention.

Read more →
Aviado ResearchAviado Research· 2026-05-04

How Bacopa Targets Both Memory and Anxiety Through Two Separate Brain Pathways

Bacopa monnieri stands out among cognitive supplements for targeting two brain systems simultaneously -- acetylcholine pathways for memory and GABA receptors for anxiety reduction. Clinical trials using 300 mg daily of a 50% bacoside-standardized extract showed measurable improvements in memory recall and anxiety scores after 8-12 weeks in older adults. Effects build gradually as bacosides accumulate in brain tissue, so standardized dosing and patience are essential -- don't expect overnight results.

Read the full Aviado analysis →

Supplements & Compounds

Must ReadNature Metabolism· 2026-11-14

Blood NAD Levels Don't Decline With Age -- They Track Heart Disease Instead

The core selling point of NMN and NR supplements -- that NAD declines with age and needs replenishing -- may not hold for healthy adults. A cross-sectional study of 1,068 adults published in Nature Metabolism found no age-related decline in whole-blood NAD; instead, low NAD correlated with cardiovascular disease markers, not biological age. If you're taking NAD precursors for general longevity, this study demands a hard look at the evidence and may suggest cardiovascular health is a more defensible target. Note that the cross-sectional design cannot establish cause and effect, and supplementation trials may still show benefit through other mechanisms.

Read more →
Clinical TrialEuropean Heart Journal Open· 2026-11-13

Blood Vessel Function Improved Within 60 Minutes of This Aging Supplement's First Dose

The STAMINA trial, published in European Heart Journal Open, found that a supplement targeting the biology of aging produced significant improvements in vascular function and blood pressure parameters -- with measurable effects appearing within just 60 minutes of the first dose. The rapid vascular response is a compelling signal, though researchers caution that lasting protection against cardiovascular disease remains unproven. If vascular longevity is a priority in your stack, this is a trial worth watching closely.

Read more →

Research & Papers

New ResearchYale University· 2026-11-14

Yale Analysis Reveals Which Anti-Aging Interventions Actually Reduce Biological Age

A Yale-led analysis of 51 clinical studies using over 110 DNA methylation biomarkers identified which prescription medications and lifestyle modifications actually reduce biological age as measured by epigenetic clocks. Metformin, caloric restriction, and aerobic exercise consistently showed the strongest effects, while many popular supplements produced little or no signal. It's the most comprehensive map yet of which interventions reliably move the needle on biological aging.

Read more →
New ResearchDiabetes, Obesity and Metabolism· 2026-11-13

Metformin Linked to 39% Lower Death Risk After COVID-19 in Study of 53,000 Patients

A Stanford-led retrospective study of 53,332 U.S. adults with type 2 diabetes found that those taking metformin before a COVID-19 infection had a 39% lower risk of dying in the following year compared to patients on DPP-4 inhibitors. Published in Diabetes, Obesity and Metabolism, the finding adds to a growing body of evidence for metformin's broad protective effects beyond blood sugar control. As an observational study it cannot prove causation, but the effect size and sample scale are hard to dismiss.

Read more →

Lifestyle & Nutrition

New ResearchNeuroscience News· 2026-11-13

Irregular Sleep Schedules -- Not Just Short Sleep -- Drive Depression and Loneliness

Analyzing five months of smart-ring data from 23,000 adults, researchers found that irregular sleep-wake schedules strongly predicted severe depression, anxiety, and loneliness -- independent of total sleep duration. The dataset's scale makes this one of the most robust real-world studies linking circadian disruption to mental health outcomes. If you use a wearable, check your sleep regularity score alongside total hours -- it may be the more important number.

Read more →

Industry & Policy

Evidence CheckScott Carney Investigates· 2026-11-13

David Sinclair Is Still Selling the Story Before the Science Exists

Investigative journalist Scott Carney lays out a detailed case that David Sinclair's Life Biosciences raised $80 million in new funding -- bringing its total to nearly $240 million -- before key supporting data existed, echoing the pattern Carney previously documented with Sinclair's resveratrol claims. The piece is sharp, heavily sourced, and directly relevant to anyone who has followed Sinclair's protocols or considered investing in longevity biotech. Required reading if you want to separate longevity science from longevity hype.

Read more →